Scientists in Australia have overturned three decades of medical belief after uncovering the true cause of severe inflammation in patients with Mevalonate Kinase Deficiency (MKD), a rare genetic immune disorder. Led by researchers at the Garvan Institute of Medical Research in collaboration with Monash University, the breakthrough study reveals that life-threatening inflammatory flares are not driven by macrophage cells as previously assumed, but rather by malfunctioning "natural killer" (NK) immune cells.
Normally, NK cells serve as the body's frontline defence against viral infections by releasing "toxic granules" to destroy infected cells. However, researchers studying patient blood samples and preclinical models discovered that in individuals with MKD, these NK cells fail to mature properly and cannot deploy their toxic ammunition. Instead, the granules remain trapped inside the cells, leaving the immune system unable to clear routine viral infections.
When these impaired NK cells fail to eliminate their targets, they compensate by releasing excessive amounts of interferon gamma, a potent inflammatory signal. This chemical surge triggers a domino effect that overactivates the wider immune system, resulting in recurring episodes of high fever, skin rashes, joint pain, and severe gastrointestinal and organ inflammation.
"This really turns on its head 30 years of dogma about what was thought to be the underlying mechanism of disease. In MKD, the primary problem is in NK cells and not in macrophages, as previously believed," said lead researcher Dr. Marcia Munoz, Group Leader in the Rogers Lab at the Garvan Institute. Study co-lead Professor Mike Rogers added that the immune cells are essentially "misfiring" and "shouting for help" when they cannot kill their targets.
Because existing therapies target macrophage signals and fail in roughly half of all MKD patients, the discovery opens the door to more effective treatments. Working alongside doctors at the Royal Children's Hospital in Melbourne, the team successfully treated a severely affected infant using baricitinib an existing medication used for rheumatoid arthritis and eczema that blocks interferon signalling resulting in fewer inflammatory flares and significant healing of gastrointestinal damage.
Reference:
Garvan Institute of Medical Research. (2026). A rare disease reveals a hidden flaw in the immune system. ScienceDaily.
